| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 2,820 | 21,050 | 13,540 | 10,140 | 1,090 |
| Sales Growth | -86.60% | +55.47% | +33.53% | +830.27% | unch |
| Net Income | -127,500 | -89,220 | -66,220 | -48,630 | -26,130 |
| Net Income Growth | -42.91% | -34.73% | -36.17% | -86.11% | -91.29% |
Tscan Therapeutics Inc (TCRX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.6700 +0.0600 (+3.73%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.6700 unch (unch) 16:10 ET
for Fri, Mar 21st, 2025
TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.
Fiscal Year End Date: 12/31